Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01931462
Other study ID # 2013-1080
Secondary ID
Status Terminated
Phase N/A
First received August 23, 2013
Last updated January 29, 2018
Start date August 2014
Est. completion date December 2016

Study information

Verified date January 2018
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Partial nephrectomy (kidney removal) is a standard therapy for clinical T1 renal (kidney) tumors. The goals of surgery are to accurately remove the tumor with no cancer cells at the edge of the remaining tissue, to limit blood loss, and preserve kidney function. The most common technique is to clamp the blood supply to the entire kidney during removal and to surgically repair the tumor bed with suture and agents to stop bleeding. This stops the blood supply to the entire kidney including the healthy tissue, which can cause damage to the remaining tissue due to a shortage of oxygen if left clamped too long.

This study uses a microwave pre-coagulation technique using the Certus 140™ to facilitate a bloodless area near the tumor for accurate tumor removal and repair, while avoiding clamping the blood supply, but its effect on the function of kidney adjacent to tumor is unknown. If adequate stoppage of bleeding is achieved using the Certus 140™ with minimal heat spreading to the remaining tissue, clamping and a shortage of oxygen can be avoided.

The hypothesis is that microwave pre-coagulation is a safe method for providing the stoppage of bleeding during partial kidney removal.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patient must have a solitary, polar, clinical T1 renal mass

2. Patient must have adequate kidney function as measured by eGFR (estimated glomerular filtration rate) greater than or equal to 50 calculated from a standard care serum creatinine performed within 30 days prior to the partial nephrectomy operation.

3. Women of child-bearing potential must have negative serum or urine pregnancy test

4. Patient must be able to give written informed consent

5. Patient must be 18 years or older

6. No blood-thinning medications, including anti-inflammatory medications, herbs and supplements for at least 1 week prior to surgery

Exclusion Criteria:

1. T stage greater than clinical T1

2. Tumor extends beyond kidney into major veins, perinephric tissues, or adrenal gland

3. Prior surgery or radiation therapy to the region of interest

4. Patient has a single functioning kidney

5. Patient has an uncorrectable coagulopathy

6. Patient is not a surgical candidate due to underlying cardiac or other serious comorbid condition

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Microwave pre-coagulation
The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.

Locations

Country Name City State
United States University of Wisconsin Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To Assess the Effectiveness of Microwave Pre-coagulation Using the Certus 140™ System for Partial Nephrectomy on Renal Function Using the Estimated Glomerular Filtration Rate. We will be measuring the change in renal function as quantified by pre- and post-surgical estimated Glomerular Filtration Rate. Change = (6 week score - Baseline score) 30 days prior to surgery (Baseline) and 6 weeks post surgery
Secondary Blood Loss To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring blood loss. We will calculate the mean, median, standard deviation, and range of values for blood loss. During the operation
Secondary Operative Time To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring operative time. We will calculate the mean, median, standard deviation, and range of values for operative time. During the operation
Secondary Clamp Time To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring clamp time. We will calculate the mean, median, standard deviation, and range of values for clamp time. During the operation
Secondary Change in Renal Function To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring the change in renal function by nuclear scan and creatinine clearance. We will calculate the mean, median, standard deviation, and range of values for change in renal function by nuclear scan and creatinine clearance. Within 30 days prior to operation and 6 weeks post operation
Secondary Change in Functional Renal Volume To assess the safety and efficacy of the Certus 140™ in establishing hemostasis by measuring the change in functional renal volume as measured by MRI. We will calculate the mean, median, standard deviation, and range of values for change in functional renal volume as measured by MRI. Within 30 days prior to operation and 6 weeks post-operation
Secondary Tumor Margin The percentage of subjects with tumor positive margins will be reported. Tissue pathology will occur during the operation and a final tissue pathology will be performed 6 weeks after the operation. During the operation and 6 weeks post-operation
Secondary Complication Rates Complication rates will be estimated using the methods of Kaplan and Meier. During the operation
See also
  Status Clinical Trial Phase
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Recruiting NCT02121730 - Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT05241561 - Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients Phase 2
Completed NCT00199888 - Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. Phase 1
Completed NCT05363072 - A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
Withdrawn NCT04127318 - Low-moderate Intensity Pedaling During Immunotherapy Administration N/A
Recruiting NCT03452774 - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting NCT05732857 - Valveless Trocar Versus Standard Trocar in Robot-assisted Complex Partial Nephrectomy N/A
Recruiting NCT03133286 - Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
Completed NCT02145559 - A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors Phase 1